Drug Discovery

Lung cancer is one of the most common and deadly types of cancer worldwide, and the ability of cancer cells to evade the body’s immune system poses a significant challenge in treating it. A team of Weill Cornell Medicine scientists recently made a significant breakthrough in understanding this process. They discovered a genetic signature that can predict patient survival and identified a key mechanism lung cancer cells use to avoid immune attacks. This groundbreaking discovery could hasten the development of treatments that can circumvent tumor defense mechanisms, increasing the chances of survival for lung cancer patients. The signaling pathway involving IRE1 and XBP1 is becoming increasingly recognized as a key player in cancer progression and immune system suppression in various types of cancer. The study, which was published in the journal Nature Communications, involved the analysis of human lung cancer datasets as well as experiments on preclinical models, and it…